Monophosphoryl lipid A enhances both humoral and cell- mediated immune responses to DNA vaccination against human immunodeficiency virus type 1

Infection and Immunity

Volumn 65, Issue 9, 1997, Pages 3520-3528

  Sasaki, Shin ^a   Tsuji, Takashi ^a   Hamajima, Kenji ^a   Fukushima, Jun ^a   Ishii, Norihisa ^a   Kaneko, Tamiko ^a   Xin, K E Qin ^a   Mohri, Hiroshi ^a   Aoki, Ichiro ^a   Okubo, Takao ^a   Nishioka, Kusuya ^b   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Viral Hepatitis Foundation of Japan   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LIPID A; PLASMID DNA;

ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION; VIRUS NEUTRALIZATION;

EID: 0030955186     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.9.3520-3528.1997     Document Type: Article

References (40)

1. Benoit, P. W., and W. D. Belt. 1970. Destruction and regeneration of skeletal muscle after treatment with a local anesthetic, bupivacaine (Marcaine). J. Anat. 107:547-556.
2. Bukawa, H., K. Sekigawa, K. Hamajima, J. Fukushima, Y. Yamada, H. Kiyono, and K. Okuda. 1995. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nat. Med. 1:681-685.
3. Carozzi, S., M. Salit, A. Cantaluppi, M. G. Nasini, S. Barocci, S. Cantarella, and S. Lamperi. 1989. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J. Clin. Microbiol. 27:1748-1753.
4. Corr, M., D. J. Lee, D. A. Carson, and H. Tighe. 1996. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184:1555-1560.
5. Cullen, B. R. 1986. Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 46:973-982.
6. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1492. Protective effect of a live attenuated SIV vaccine with a deletion of nef gene. Science 258:1938-1941.
7. Davis, H. L., M. L. Michel, and R. G. Whalen. 1995. Use of plasmid DNA for direct gene transfer and immunization. Ann. N. Y. Acad. Sci. 772:21-29.
8. Davis, H. L., and R. G. Whalen. 1995. DNA-based immunization: prospects for a hepatitis B vaccine, p. 147-160. In G. Gregoriadis, B. McCormack, and A. C. Allison (ed.), Vaccines-new generation immunological adjuvants, vol. 282. Plenum Press, New York, N.Y.
9. Gustafson, G. L., and M. J. Rhodes. 1992. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol. 143:483-488.
10. + T-cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J. Exp. Med. 176:1335-1341.
11. Hassett, D. E., and J. L. Whitton. 1996. DNA immunization. Trends Microbiol. 4:307-312.
12. Ishizuka, S. T., P. Piacente, J. Silva, and E. M. Mishkin. 1995. IgG subtype is correlated with efficacy of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J. Infect. Dis. 172:1108-1111.
13. Keefer, M. C., B. S. Graham, M. J. McElrath, T. J. Matthews, and D. M. Stablein. 1996. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. AIDS Res. Hum. Retroviruses 12:683-693.
14. Kumar, V., and E. Sercarz. 1996. Genetic vaccination: the advantages of going naked. Nat. Med. 2:857-859.
15. Layton, G. T., S. J. Harris, A. J. Gearing, P. M. Hill, J. S. Cole, J. C. Griffiths, N. R. Burns, A. J. Kingsman, and S. E. Adams. 1993. Induction of HIV-specific cytoloxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J. Immunol. 151:1097-1107.
16. Lu, S., J. C. Santoro, D. H. Fuller, J. R. Haynes, and H. L. Robinson. 1995. Use of DNAs expressing HIV-1 Env and non infectious HIV-1 particles to raise antibody responses in mice. Virology 209:147-154.
17. Malim, M. H., J. Hauber, R. Fenrick, and B. R. Cullen. 1988. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335:181-183.
18. Mor, G., M. Singla, A. D. Steinberg, S. L. Hoffman, K. Okuda, and D. M. Klinman. 1997. Do DNA vaccines induce autoimmune disease? Hum. Gene Ther. 8:293-300.
19. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of murine helper T cell clone. 1. Definition according to the profiles of lymphokine activities and secreted protein. J. Immunol. 138:2348-2357.
20. Newman, M. J., K. J. Munroe, C. A. Anderson, C. I. Murphy, D. L. Panicali, J. R. Seals, J. Y. Wu, M. S. Wyand, and C. R. Kensil. 1994. Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant. AIDS Res. Hum. Retroviruses 10:853-861.
21. Okuda, K., H. Bukawa, K. Hamajima, S. Kawamoto, K. Sekigawa, Y. Yamada, S. Tanaka, N. Ishi, I. Aoki, M. Nakamura, H. Yamamoto, B. R. Cullen, and J. Fukushima. 1995. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res. Hum. Retroviruses 11:933-943.
22. Okuda, K., H. Bukawa, S. Kawamoto, M. Imai, T. Saito, P. Phanuphak, and K. Hamajima. 1994. A serologic analysis and amino acid sequence of the V3 region of human immunodeficiency virus from carriers in Bangkok. J. Infect. Dis. 169:227-228.
23. Okuda, K., N. Ishii, Z. Ikezawa, T. Takahashi, K. Arai, and I. Tadokoro. 1982. Delayed type hypersensitivity to hen egg-white lysozyme. I. The surface phenotypes of suppressor T cells induced by intravenous infection of lysozyme-modified spleen cells and their molecular interactions. Microbiol. Immunol. 26:879-911.
24. Powell, M. F., D. J. Eastman, A. Lim, C. Lucas, M. Peterson, J. Vennari, R. P. Weissburg, T. Wrin, C. R. Kensil, and M. J. Newman. 1995. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs. AIDS Res. Hum. Retroviruses 11:203-209.
25. Putney, S. D., T. J. Matthews, W. G. Robey, D. L. Lynn, G. M. Robert, W. T. Mueller, A. J. Langlois, J. Ghrayeb, S. J. Petteway, and K. J. Weinhold. 1986. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science 234:1392-1395.
26. Rickman, L. S., D. M. Gordon, R. J. Wistar, U. Krzych, M. Gross, M. R. Hollingdale, J. E. Egan, J. D. Chulay, and S. L. Hoffman. 1991. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoitc protein vaccine. Lancet 337: 998-1001.
27. Robinson, H. L., S. Lu, F. Mustafa, E. Johnson, J. C. Santoro, J. Arthos, J. Winsink, J. I. Mullins, D. Montefiori, Y. Yasutomi, N. L. Letvin, J. R. Haynes, K. Manson, and M. Wyand. 1995. Simian immunodeficiency virus DNA vaccine trial in macaques. Ann. N. Y. Acad. Sci. 772:209-211.
28. Schneerson, R., A. Fattom, S. C. Szu, D. Bryla, J. T. Ulrich, J. A. Rudbach, G. Schiffman, and J. B. Robbins. 1991. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J. Immunol. 147:2136-2140.
29. Takahashi, H., R. N. Germain, B. Moss, and J. A. Berzofsky. 1990. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 II-restricted help for itself. J. Exp. Med. 171:571-576.
30. Ulmer, J. B., R. R. Deck, C. M. Dewitt, J. I. Donnhly, and M. A. Liu. 1996. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 89:59-67.
31. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, L. A. Hawe, R. R. Leander, D. Martinez, H. C. Perry, J. W. Shiver, D. L. Montgomery, and M. A. Liu. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749.
32. Ulrich, J. T., and K. R. Myers. 1995. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions, p. 495-523. In M. F. Powell and M. J. Newman (ed.), Vaccine design. Plenum Press, New York, N.Y.
33. Vilquin, J. T., B. Guerette, I. Kinoshita, B. Roy, M. Goulet, C. Gravel, R. Roy, and J. P. Tremblay. 1995. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum. Gene Ther. 6:1391-1401.
34. Vitadello, M., M. V. Schiaffino, A. Picard, M. Scarpa, and S. Schiaffino. 1994. Gene transfer in regenerating muscle. Hum. Gene Ther. 5:11-18.
35. Vogel, F. R. 1995. The role of adjuvants in retroviral vaccines. Int. J. Immunopharmacol. 17:85-90.
36. Wechsler, D. S., and P. A. L. Kongshavn. 1986. Heat-labile IgG2a antibodies effect cure of Trypanosoma musculi infection in C57B1/6 mice. J. Immunol. 137:2968-2972.
37. Wells, D. J. 1993. Improved gene transfer by direct plasmid injection associated with regeneration in mouse skeletal muscle. FEBS Lett. 332:179-182.
38. Xiang, Z. Q., and H. C. J. Ertl. 1995. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129-135.
39. Xiang, Z. Q., S. L. Spitalnik, J. Cheng, J. Erikson, B. Wojczyk, and H. C. J. Ertl. 1995. Immune response to nucleic acid vaccine to rabies virus. Virology 209:269-279.
40. Zhou, F., and L. Huang. 1993. Monophosphoryl lipid A enhances specilic CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine 11:1139-1144.